YOYoshifumi Ohashi

Yoshifumi Ohashi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Yoshifumi Ohashi has a total of 24 co-authors. Here are the top co-authors by number of shared publications:

  • Shiro Imagama

    Department of Orthopedic Surgery, Nagoya University Graduate School of Medicine , 65 Tsurumai-cho, Showa-ku, Nagoya, Aichi 466-8550

    6 shared publications
  • Kenya Terabe

    Department of Orthopedic Surgery, Nagoya University Graduate School of Medicine , 65 Tsurumai-cho, Showa-ku, Nagoya, Aichi 466-8550

    5 shared publications
  • Mochihito Suzuki

    Department of Orthopedic Surgery Nagoya University Graduate School of Medicine Nagoya Japan

    5 shared publications
  • Shuji Asai

    Department of Orthopedic Surgery, Nagoya University Graduate School of Medicine , 65 Tsurumai-cho, Showa-ku, Nagoya, Aichi 466-8550

    5 shared publications
  • Yasumori Sobue

    Department of Orthopedic Surgery Japan Red Cross, Aichi Medical Center, Nagoya Daiichi Hospital Nagoya Japan

    5 shared publications
  • Kenya Terabe

    Department of Orthopedic Surgery and Rheumatology Nagoya University Graduate School of Medicine Nagoya Japan

    4 shared publications

Latest Publications

  • Grip strength asymmetry as a better indicator of residual hand symptoms than absolute grip strength after achieving treat-to-target in rheumatoid arthritis

    by Yoshifumi Ohashi, Mochihito Suzuki, Yasumori Sobue, Kenya Terabe, Shuji Asai, Shiro Imagama, Nobunori Takahashi

    Objective: This study aimed to identify factors associated with residual hand symptoms in well-controlled rheumatoid arthritis (RA) patients. Methods: Data from 464 RA patients with DAS28-ESR < 3.2 and bilateral grip strength measurements were analysed. Grip strength asymmetry was defined as a grip difference rate ≥ 20%, calculated as follows: (Stronger hand grip strength—Weaker hand grip strength)/Stronger hand grip strength × 100. Patients were grouped by the presence (n = 107) or absence (n = 357) of hand symptoms. Multivariable logistic regression was used to identify associated factors. The relationship between grip strength asymmetry and hand symptoms was also examined. Results: Patients with hand symptoms were younger (64.3 versus 69.1 years), had higher DAS28-ESR scores (2.42 versus 2.04), and a greater grip difference rate (19.9% versus 14.5%) compared to those without. Multivariable analysis showed that age (OR 0.97), Steinbrocker stage (OR 1.36), and grip difference rate (OR 1.02) were independently associated with hand symptoms. The prevalence of hand symptoms and swelling was higher in the grip strength asymmetry group than in the non-asymmetry group (hand symptoms: 30.8% versus 19.8%; swelling: 11.2% versus 5.3%). Conclusions: Grip strength asymmetry may serve as a simple and accessible marker for residual joint symptoms in RA patients achieving T2T.

  • Investigation of the Risk of Frailty Progression Based on 5‐Year Data in Patients With Rheumatoid Arthritis: A Multicenter Observational Study (T‐ FLAG )

    by Yoshifumi Ohashi, Mochihito Suzuki, Yasumori Sobue, Kenya Terabe, Shuji Asai, Shiro Imagama, Nobunori Takahashi

    Objectives: To examine risk factors for non‐frailty rheumatoid arthritis (RA) patients progressing to frailty. Methods: A total of 304 RA patients with records for frailty assessment based on the Japanese Cardiovascular Health Study (J‐CHS) criteria from 2020 to 2024 were included. Patients classified as non‐frail (J‐CHS scores 0–3) in 2020 were followed annually, and those who did and did not progress to frailty were categorized into the frailty progression ( n = 100) and non‐frailty progression ( n = 204) groups, respectively. Risk factors for frailty progression were analyzed using the Cox proportional hazards model. Changes in DAS28‐ESR and HAQ‐DI between baseline and frailty progression were compared using a paired t ‐test. Results: Compared to the non‐frailty progression group, the frailty progression group was older (62.9 vs. 68.5 years) and had a longer duration of disease (9.1 vs. 14.2 years), lower methotrexate (MTX) use (74.4% vs. 56.1%), higher mean DAS28‐ESR (2.40 vs. 2.77), and higher HAQ‐DI (0.17 vs. 0.45). Both groups had high biological/targeted synthetic disease‐modifying antirheumatic drugs (b/tsDMARDs) use rates (34.3% vs. 42.0%). Risk factors for frailty events included age ≥ 65 years (HR 1.86), duration of disease ≥ 10 years (HR 1.64), DAS28‐ESR < 2.6 (HR 0.64), HAQ‐DI ≤ 0.5 (HR 0.45), and MTX use (HR 0.63). DAS28‐ESR remained at a low disease activity level (baseline vs. frailty progression: 2.77 vs. 2.90), whereas HAQ‐DI worsened at frailty progression compared to baseline (0.45 vs. 0.66). Conclusions: Optimizing MTX use and achieving DAS/HAQ remission are crucial for preventing frailty. Non‐medication‐based approaches are also essential.


  • Open Access

    Association between frailty and oral function in rheumatoid arthritis patients: A multi-center, observational study

    by Yasumori Sobue, Mochihito Suzuki, Yoshifumi Ohashi, Ryo Sato, Yusuke Ohno, Junya Hasegawa, Takaya Sugiura, Kenya Terabe, Shuji Asai, Shiro Imagama

    Objectives: This study aims to investigate the association between frailty and oral function in rheumatoid arthritis (RA) patients and to identify practical markers for early frailty detection and potential intervention strategies. Patients and methods: A multi-center observational cohort study (T-FLAG) included a total of 661 RA patients (186 males, 475 females; mean age: 68.5±13.5 years; range, 18 to 100 years) between June 2023 and August 2023. Frailty was assessed using the Kihon Checklist (KCL) (frailty: score ≥8). Oral function scores were based on Question 13 (“difficulty eating hard foods”), Question 14 (“choking”), and Question 15 (“dry mouth”) of the KCL. Receiver operating characteristic (ROC) curves were generated to assess the association between frailty and oral function scores. Multivariate logistic regression was used to analyze factors associated with oral function. Results: Among the 661 participants, 39.5% were frail. Frailty rates tended to increase with increasing oral function scores. The optimal cut-off score for oral function corresponding to frailty was 2 points, with a specificity of 89.2% and a sensitivity of 54.8%. Multivariate analysis identified age and Health Assessment Questionnaire-Disability Index (HAQ-DI) as significant factors associated with oral function decline (i.e., a total score of ≥2 for Questions 13-15 of the KCL). Conclusion: Frailty is strongly associated with oral function decline in RA patients. This finding highlights the importance of monitoring the oral function of RA patients, since it not only reflects physical function, but also serves as a potential marker of frailty. Targeted interventions to improve oral function may play a vital role in reducing frailty risk and enhancing the overall well-being of RA patients.


  • Open Access

    The association between difficult-to-treat rheumatoid arthritis and probable sarcopenia

    by Yoshifumi Ohashi, Mochihito Suzuki, Yasumori Sobue, Kenya Terabe, Shuji Asai, Nobunori Takahashi, Shiro Imagama

    Objectives: To identify factors associated with probable sarcopenia in patients with rheumatoid arthritis (RA). Methods: Probable sarcopenia was diagnosed using the SARC-F questionnaire. Patients with difficult-to-treat RA (D2T-RA) were defined as those with a history of using ≥2 biological/targeted synthetic (b/ts) disease-modifying antirheumatic drugs (b/tsDMARDs) who had moderate or high disease activity. Among 486 patients, 101 were classified into the probable sarcopenia group (SARC-F ≥4), and 385 were classified into the non-probable sarcopenia group (SARC-F <4). Factors associated with probable sarcopenia were examined using multiple logistic regression analysis. Additionally, patients were divided into the D2T-RA (n = 38) and non-D2T-RA (n = 448) groups, and the proportion of probable sarcopenia and RA treatment status were compared. Results: Factors associated with probable sarcopenia included age [adjusted odds ratio (OR): 1.03], body mass index (OR: 1.16), D2T-RA (OR: 3.39), and Health Assessment Questionnaire-Disability Index (OR: 1.38), and diabetes mellitus (OR: 2.77). The proportion of probable sarcopenia was significantly higher (60.5% vs. 17.4%), and the rate of methotrexate use was significantly lower (34.2% vs. 64.1%), in the D2T-RA group than in the non-D2T-RA group. Moreover, in the D2T-RA group, most patients used two or three b/tsDMARDs (two: 68.4%, three: 21.1%). Conclusions: D2T-RA was associated with probable sarcopenia. Tight control by treatment enhancement may help overcome sarcopenia.


  • Association between sarcopenia and locomotive syndrome in rheumatoid arthritis patients: A multicenter observational study (T‐FLAG)

    by Yasumori Sobue, Mochihito Suzuki, Yoshifumi Ohashi, Ryo Sato, Hironobu Kosugiyama, Yusuke Ohno, Junya Hasegawa, Takaya Sugiura, Kenya Terabe, Shuji Asai, et al.


  • Associations of frailty with RA-ILD and poor control of disease activity in patients with rheumatoid arthritis: A multi-center retrospective observational study

    by Yoshifumi Ohashi, Nobunori Takahashi, Yasumori Sobue, Mochihito Suzuki, Ryo Sato, Masataka Maeda, Daisuke Kihira, Kenji Kishimoto, Kenya Terabe, Shuji Asai, et al.


  • Well‐controlled disease activity with drug treatment will not improve the frailty status of RA patients to robust state: A multicenter observational study (T‐FLAG)

    by Yoshifumi Ohashi, Nobunori Takahashi, Yasumori Sobue, Mochihito Suzuki, Ryo Sato, Masataka Maeda, Kenya Terabe, Shuji Asai, Shiro Imagama

    Objectives: To investigate a plateau in treatment enhancement for improving the frailty status of rheumatoid arthritis (RA) patients.Methods: A total of 345 RA patients who were not robust in 2021 were assigned to the improved (“robust 2022,” n = 51) and non‐improved (“pre‐frailty/frailty 2022,” n = 294) groups. Factors associated with “robust 2022” were examined by logistic regression analysis. Patients were assigned to the stable (Follow‐up mean DAS28‐ESR in 2020 and 2021 < 3.2, n = 225) and unstable (≥3.2, n = 120) groups, which were further divided into the non‐improved (stable: n = 180, unstable: n = 114) and improved (stable: n = 45, unstable: n = 6) groups. Factors influencing Japanese Cardiovascular Health Study (J‐CHS) score were examined by multiple regression analysis. Changes over 2 years were compared between the non‐improved and improved groups of the stable group.Results: The associated factor of “robust 2022” was the follow‐up meanDAS28‐ESR in 2020 and 2021 < 3.2 (i.e., stable state) (OR: 4.01). Follow‐up mean DAS28‐ESR in 2020 and 2021 was associated with J‐CHS score (T = 2.536, p = .013) only in the unstable group. In the stable group, HAQ‐DI was lower (2020: 0.32 vs. 0.16; 2021: 0.32 vs. 0.17; 2022: 0.32 vs. 0.21), and the proportion of J‐CHS: Q4 (weakness) was lower (2020: 48.4 vs. 17.8%; 2021: 55.0 vs. 29.2%; 2022: 50.4 vs. 0%), in the improved group than in the non‐improved group, whereas both groups maintained clinical and functional remission over 2 years.Conclusions: Drug treatment to maintain well‐controlled disease activity alone is insufficient for improving patients' frailty status after achieving treat‐to‐target goals, suggesting the need for multifaceted approaches.


  • Disease activity at baseline is an independent predictor of frailty at one year in pre-frail patients with rheumatoid arthritis; a multicenter retrospective observational study

    by Yoshifumi Ohashi, Nobunori Takahashi, Yasumori Sobue, Mochihito Suzuki, Kyosuke Hattori, Kenji Kishimoto, Kenya Terabe, Shuji Asai, Toshihisa Kojima, Masayo Kojima, et al.